Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of envafolimab alone or with lenvatinib in advanced endometrial cancer
CTR20212718Phase 2Active
- Sponsor
- Sichuan Sigmaker Pharmaceutical
- Start
- Apr 2022
- Modality
- Small Molecules, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of envafolimab and lenvatinib in endometrial cancer (EC) (2 arms), sponsored by Sichuan Sigmaker Pharmaceutical. Primary endpoint: Objective response rate. Started Apr 2022; status: active.
02
Drugs
envafolimablenvatinib
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on CTR20212718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212718.